TA
ACRS icon

Teachers Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Teachers Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1.58M Buy
263,595
+206,944
+365% +$1.37M ﹤0.01% 2088
2018
Q4 		$419K Buy
56,651
+8,361
+17% +$86.2K ﹤0.01% 2585
2018
Q3 		$701K Sell
48,290
-46
-0.1% -$788 ﹤0.01% 2492
2018
Q2 		$965K Buy
48,336
+6,001
+14% +$111K ﹤0.01% 2339
2018
Q1 		$742K Buy
42,335
+236
+0.6% +$5K ﹤0.01% 2357
2017
Q4 		$1.04M Buy
42,099
+3,273
+8% +$79.7K ﹤0.01% 2210
2017
Q3 		$1M Buy
38,826
+2,075
+6% +$55.6K ﹤0.01% 2232
2017
Q2 		$997K Buy
36,751
+16,783
+84% +$456K ﹤0.01% 2237
2017
Q1 		$595K Buy
19,968
+2,719
+16% +$78.4K ﹤0.01% 2451
2016
Q4 		$468K Buy
17,249
+3,435
+25% +$87.6K ﹤0.01% 2575
2016
Q3 		$354K Sell
13,814
-398
-3% -$8.44K ﹤0.01% 2641
2016
Q2 		$262K Buy
14,212
+6,772
+91% +$134K ﹤0.01% 2756
2016
Q1 		$141K Buy
7,440
+1,753
+31% +$33.5K ﹤0.01% 2885
2015
Q4 		$153K Buy
+5,687
New +$111K ﹤0.01% 2944

Other funds holding ACRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Teachers Advisors's ACRS Position: Q1 2019 in Review

Teachers Advisors increased its Aclaris Therapeutics (ACRS) stake by 365% in Q1 2019, buying an estimated $1.37M and bringing the position to 263,595 shares worth $1.58M. The position accounts for ﹤0.01% of the portfolio, ranked #2088.

Teachers Advisors first reported a position in ACRS in Q4 2015 and has held it in 14 quarters since. 95 funds tracked by Wall St. Rank hold ACRS as of Q1 2019.

  • Teachers Advisors held 263,595 shares of Aclaris Therapeutics worth $1.58M as of Q1 2019.
  • Teachers Advisors bought 206,944 Aclaris Therapeutics shares in Q1 2019, an estimated $1.37M.
  • Aclaris Therapeutics made up ﹤0.01% of Teachers Advisors's portfolio in Q1 2019, its #2088 holding.
  • Teachers Advisors first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 14 quarters since.
  • 95 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2019.

Based on Teachers Advisors's 13F filing for Q1 2019, filed 14 May 2019.